Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2NET 1Endocrine 1

Conditions

Parkinson Disease 1Neuroendocrine Tumors 1Neuroblastoma 1Lewy Body Disease 1Glioma 1Congenital Hyperinsulinism 1Brain Neoplasms 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 91Gemcitabine 81Paclitaxel 79Docetaxel 70Capecitabine 64Oxaliplatin 53Fluorouracil 51Specimen Handling 50Magnetic Resonance Spectroscopy 49Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 45Drug Therapy 39Leucovorin 38Doxorubicin 37Pemetrexed 35Irinotecan 34Injections 30Rituximab 29Vincristine 28Trastuzumab 26Radiosurgery 26Prednisone 26Lenalidomide 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × fluorodopa F 18 × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

NCT05512403 2024-09-19

KING

Central Hospital, Nancy, France

Phase 3 Recruiting
88 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡